Pharmaceutical industry DSM Announces Marketing and Sales Alliance with Indoco
To strengthen its position in Asia, Dutch DSM announced the formation of a marketing and sales alliance with India's Indoco. DSM intends to sell APIs produced by its Indian partner, the firms explained.
Mumbai/India – In line with DSM and Indoco's strategy, this agreement represents a step to forge an alliance to expand presence in markets across the globe. The API’s manufactured by Indoco and to be marketed and sold by DSM are used in the production of pharmaceutical Finished Dosages. This alliance will leverage Indoco's product development and cGMP (current Good Manufacturing Practices) compliant manufacturing capabilities and DSM's market access. In addition DSM will use its operation and quality systems to allow faster growth in regulated markets.
"Growth Via Partnerships"
Alexander Wessels, President and Chief Executive Officer, DSM Pharmaceutical Products (DPP) stated, “This is a step in our announced strategy to accelerate growth via partnerships and expansion in Asia to build a product portfolio along side our custom manufacturing operations, supplying access to high demand treatments. It allows DPP to build a competence base in India.” The Indoco alliance is anchored in DSM's API business, DSM Pharma Chemicals, headquartered in Austria.
Indoco Plans to Strengthen Global Presence
Suresh G. Kare, Chairman & Managing Director, Indoco Remedies, commented, “Today in the era of alliances and partnerships, organizations are coming together to penetrate and capture a larger share of the potential opportunities in the market place. Indoco is active in forging such alliances and this one with DSM is a step in that direction. This alliance offers a great opportunity to expand our global presence with a well established partner."